• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺动脉高压中 BMPR2 基因的分子和功能特征。

Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension.

机构信息

Dep. Biochemistry, Genetics and Immunology. Faculty of Biology, University of Vigo, As Lagoas Marcosende S/N, 36310, Vigo, Spain.

Grupo de Investigación Enfermedades Raras y Medicina Pediátrica, Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain.

出版信息

Sci Rep. 2017 May 15;7(1):1923. doi: 10.1038/s41598-017-02074-8.

DOI:10.1038/s41598-017-02074-8
PMID:28507310
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5432510/
Abstract

Pulmonary arterial hypertension is a progressive disease that causes the obstruction of precapillary pulmonary arteries and a sustained increase in pulmonary vascular resistance. The aim was to analyze functionally the variants found in the BMPR2 gene and to establish a genotype-phenotype correlation. mRNA expression studies were performed using pSPL3 vector, studies of subcellular localization were performed using pEGFP-N1 vector and luciferase assays were performed using pGL3-Basic vector. We have identified 30 variants in the BMPR2 gene in 27 of 55 patients. In 16 patients we detected pathogenic mutations. Minigene assays revealed that 6 variants (synonymous, missense) result in splicing defect. By immunofluorescence assay, we observed that 4 mutations affect the protein localization. Finally, 4 mutations located in the 5'UTR region showed a decreased transcriptional activity in luciferase assays. Genotype-phenotype correlation, revealed that patients with pathogenic mutations have a more severe phenotype (sPaP p = 0.042, 6MWT p = 0.041), a lower age at diagnosis (p = 0.040) and seemed to have worse response to phosphodiesterase-5-inhibitors (p = 0.010). Our study confirms that in vitro expression analysis is a suitable approach in order to investigate the phenotypic consequences of the nucleotide variants, especially in cases where the involved genes have a pattern of expression in tissues of difficult access.

摘要

肺动脉高压是一种进行性疾病,可导致毛细血管前肺动脉阻塞和肺血管阻力持续增加。目的是分析 BMPR2 基因中发现的变异,并建立基因型-表型相关性。使用 pSPL3 载体进行 mRNA 表达研究,使用 pEGFP-N1 载体进行亚细胞定位研究,使用 pGL3-Basic 载体进行荧光素酶测定。我们在 55 名患者中的 27 名中发现了 BMPR2 基因中的 30 个变异。在 16 名患者中检测到致病性突变。小基因分析表明,6 个变异(同义、错义)导致剪接缺陷。通过免疫荧光测定,我们观察到 4 个突变影响蛋白质定位。最后,4 个位于 5'UTR 区域的突变在荧光素酶测定中显示出转录活性降低。基因型-表型相关性表明,具有致病性突变的患者具有更严重的表型(sPaP p=0.042,6MWT p=0.041),诊断年龄更低(p=0.040),并且似乎对磷酸二酯酶-5 抑制剂的反应更差(p=0.010)。我们的研究证实,体外表达分析是一种合适的方法,可用于研究核苷酸变异的表型后果,特别是在涉及基因在难以获得的组织中表达的情况下。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/249909199f6b/41598_2017_2074_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/deaeb78e4f09/41598_2017_2074_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/0b0df7273308/41598_2017_2074_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/4dc92b4dc57d/41598_2017_2074_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/e83510b56d73/41598_2017_2074_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/9cc498d911c9/41598_2017_2074_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/9bbde69b7c3f/41598_2017_2074_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/3e8f6204c2a7/41598_2017_2074_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/249909199f6b/41598_2017_2074_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/deaeb78e4f09/41598_2017_2074_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/0b0df7273308/41598_2017_2074_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/4dc92b4dc57d/41598_2017_2074_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/e83510b56d73/41598_2017_2074_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/9cc498d911c9/41598_2017_2074_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/9bbde69b7c3f/41598_2017_2074_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/3e8f6204c2a7/41598_2017_2074_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f32/5432510/249909199f6b/41598_2017_2074_Fig8_HTML.jpg

相似文献

1
Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension.肺动脉高压中 BMPR2 基因的分子和功能特征。
Sci Rep. 2017 May 15;7(1):1923. doi: 10.1038/s41598-017-02074-8.
2
[Bone morphogenetic protein type II receptor gene promoter mutation-142G > A in a patient with familial pulmonary arterial hypertension].[一名家族性肺动脉高压患者的骨形态发生蛋白II型受体基因启动子突变-142G>A]
Zhonghua Yi Xue Za Zhi. 2009 Feb 3;89(4):230-4.
3
Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.遗传性肺动脉高压伴 BMPR2 突变患者的血液动力学和临床发病情况。
Respir Res. 2011 Jul 29;12(1):99. doi: 10.1186/1465-9921-12-99.
4
Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension.肺动脉高压患者中BMPR2、ACVRL1和KCNA5基因的新型突变与血流动力学参数
PLoS One. 2014 Jun 17;9(6):e100261. doi: 10.1371/journal.pone.0100261. eCollection 2014.
5
5'UTR repeat polymorphisms of the BMPR2 gene in children with pulmonary hypertension associated with congenital heart disease.BMPR2 基因 5'UTR 重复多态性与先天性心脏病相关肺动脉高压患儿
Heart Lung Circ. 2013 Mar;22(3):204-10. doi: 10.1016/j.hlc.2012.09.004. Epub 2012 Oct 24.
6
Novel promoter and exon mutations of the BMPR2 gene in Chinese patients with pulmonary arterial hypertension.中国肺动脉高压患者中BMPR2基因的新型启动子和外显子突变
Eur J Hum Genet. 2009 Aug;17(8):1063-9. doi: 10.1038/ejhg.2009.3. Epub 2009 Feb 18.
7
Sequence variants in BMPR2 and genes involved in the serotonin and nitric oxide pathways in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: relation to clinical parameters and comparison with left heart disease.骨形成蛋白受体 2 中的序列变异和涉及 5-羟色胺和一氧化氮通路的基因在特发性肺动脉高压和慢性血栓栓塞性肺动脉高压中的作用:与临床参数的关系及与左心疾病的比较。
Respiration. 2010;79(4):279-87. doi: 10.1159/000250322. Epub 2009 Oct 17.
8
BMPR2 mutations influence phenotype more obviously in male patients with pulmonary arterial hypertension.骨形态发生蛋白受体2(BMPR2)突变在男性肺动脉高压患者中对表型的影响更为明显。
Circ Cardiovasc Genet. 2012 Oct 1;5(5):511-8. doi: 10.1161/CIRCGENETICS.111.962209. Epub 2012 Aug 25.
9
Genetic variants in a Polish population of patients with pulmonary arterial hypertension: sequencing of BMPR2, ALK1, and ENG genes.波兰肺动脉高压患者群体中的遗传变异:BMPR2、ALK1 和 ENG 基因测序。
Kardiol Pol. 2018;76(5):852-859. doi: 10.5603/KP.a2018.0034. Epub 2018 Jan 19.
10
Characterization of the BMPR2 5'-untranslated region and a novel mutation in pulmonary hypertension.骨形态发生蛋白受体2(BMPR2)5'-非翻译区的特征及肺动脉高压中的一种新突变
Am J Respir Crit Care Med. 2007 Oct 15;176(8):819-24. doi: 10.1164/rccm.200701-164OC. Epub 2007 Jul 19.

引用本文的文献

1
A highly mobile adeno-associated virus targeting vascular smooth muscle cells for the treatment of pulmonary arterial hypertension.一种靶向血管平滑肌细胞用于治疗肺动脉高压的高迁移性腺相关病毒。
Nat Biomed Eng. 2025 Apr 29. doi: 10.1038/s41551-025-01379-8.
2
Emerging role of BMPs/BMPR2 signaling pathway in treatment for pulmonary fibrosis.BMPs/BMPR2 信号通路在肺纤维化治疗中的新作用。
Biomed Pharmacother. 2024 Sep;178:117178. doi: 10.1016/j.biopha.2024.117178. Epub 2024 Aug 13.
3
Design and Synthesis of Pyrazole-Based Macrocyclic Kinase Inhibitors Targeting BMPR2.

本文引用的文献

1
Complex inheritance in Pulmonary Arterial Hypertension patients with several mutations.肺动脉高压患者的多种突变的复杂遗传。
Sci Rep. 2016 Sep 15;6:33570. doi: 10.1038/srep33570.
2
Mutational and clinical analysis of the ENG gene in patients with pulmonary arterial hypertension.肺动脉高压患者ENG基因的突变与临床分析
BMC Genet. 2016 Jun 4;17(1):72. doi: 10.1186/s12863-016-0384-3.
3
Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension.
靶向骨形态发生蛋白受体2(BMPR2)的吡唑基大环激酶抑制剂的设计与合成
ACS Med Chem Lett. 2023 May 30;14(6):833-840. doi: 10.1021/acsmedchemlett.3c00127. eCollection 2023 Jun 8.
4
Transcription factors in the pathogenesis of pulmonary arterial hypertension-Current knowledge and therapeutic potential.转录因子在肺动脉高压发病机制中的作用——当前认知与治疗潜力
Front Cardiovasc Med. 2023 Jan 6;9:1036096. doi: 10.3389/fcvm.2022.1036096. eCollection 2022.
5
Future Perspectives of Pulmonary Hypertension Treatment.肺动脉高压治疗的未来展望
Acta Cardiol Sin. 2022 Jul;38(4):435-442. doi: 10.6515/ACS.202207_38(4).20220331A.
6
CRISPR-mediated Bmpr2 point mutation exacerbates late pulmonary vasculopathy and reduces survival in rats with experimental pulmonary hypertension.CRISPR 介导的 Bmpr2 点突变加剧大鼠实验性肺动脉高压的晚期肺血管病变并降低其生存率。
Respir Res. 2022 Apr 8;23(1):87. doi: 10.1186/s12931-022-02005-w.
7
Disrupting upstream translation in mRNAs is associated with human disease.破坏信使核糖核酸(mRNA)的上游翻译与人类疾病相关。
Nat Commun. 2021 Mar 9;12(1):1515. doi: 10.1038/s41467-021-21812-1.
8
Identifying Potential Mutations Responsible for Cases of Pulmonary Arterial Hypertension.确定导致肺动脉高压病例的潜在突变
Appl Clin Genet. 2021 Mar 11;14:113-124. doi: 10.2147/TACG.S260755. eCollection 2021.
9
Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients.启动子变异影响肺动脉高压患者的基因表达。
Genes (Basel). 2020 Oct 6;11(10):1168. doi: 10.3390/genes11101168.
10
Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective.肺动脉高压与慢性血栓栓塞性肺动脉高压:免疫学视角
J Clin Med. 2020 Feb 19;9(2):561. doi: 10.3390/jcm9020561.
骨形态发生蛋白2型受体突变非依赖机制导致特发性肺动脉高压中骨形态发生蛋白信号传导中断
Am J Respir Cell Mol Biol. 2016 Oct;55(4):564-575. doi: 10.1165/rcmb.2015-0402OC.
4
Towards Increasing the Clinical Relevance of In Silico Methods to Predict Pathogenic Missense Variants.提高计算机模拟方法预测致病性错义变异的临床相关性
PLoS Comput Biol. 2016 May 12;12(5):e1004725. doi: 10.1371/journal.pcbi.1004725. eCollection 2016 May.
5
Functional mutations in 5'UTR of the BMPR2 gene identified in Chinese families with pulmonary arterial hypertension.在中国肺动脉高压家系中鉴定出的BMPR2基因5'非翻译区的功能性突变。
Pulm Circ. 2016 Mar;6(1):103-8. doi: 10.1086/685078.
6
BMPR2 gene therapy for PAH acts via Smad and non-Smad signalling.用于治疗肺动脉高压的骨形态发生蛋白受体2(BMPR2)基因疗法通过Smad和非Smad信号传导发挥作用。
Respirology. 2016 May;21(4):727-33. doi: 10.1111/resp.12729. Epub 2016 Jan 26.
7
Exonic Splicing Mutations Are More Prevalent than Currently Estimated and Can Be Predicted by Using In Silico Tools.外显子剪接突变比目前估计的更为普遍,并且可以通过使用计算机工具进行预测。
PLoS Genet. 2016 Jan 13;12(1):e1005756. doi: 10.1371/journal.pgen.1005756. eCollection 2016 Jan.
8
Differential regulation of translation and endocytosis of alternatively spliced forms of the type II bone morphogenetic protein (BMP) receptor.II型骨形态发生蛋白(BMP)受体可变剪接形式的翻译与内吞作用的差异调控
Mol Biol Cell. 2016 Feb 15;27(4):716-30. doi: 10.1091/mbc.E15-08-0547. Epub 2016 Jan 6.
9
Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects.肺动脉高压:关于已确定和新出现的分子遗传缺陷的当前观点
Hum Mutat. 2015 Dec;36(12):1113-27. doi: 10.1002/humu.22904. Epub 2015 Oct 12.
10
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015 ESC/ERS 肺动脉高压诊断与治疗指南:欧洲心脏病学会(ESC)和欧洲呼吸学会(ERS)肺动脉高压诊断与治疗工作组制定:该指南得到了欧洲儿科和先天性心脏病协会(AEPC)以及国际心肺移植学会(ISHLT)的认可。
Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29.